Claims for Patent: 4,508,828

Summary for Patent: 4,508,828

Title:	Bioassay of parathyroid hormone
Abstract:	A method is disclosed for extraction, concentration, and bioassay measurement of the concentration of bioactive parathyroid peptides in biological or other fluids. Parathyroid peptides are extracted from the fluid by a support-antibody matrix specific to the N-terminal region. The bioassay is directed to the extracted parathyroid peptides. The volume of the medium containing the extracted parathyroid peptides and tissue, cells or tissue extracts with adenylate cyclase-coupled parathyroid hormone receptors may be chosen to be significantly less than the volume of biological or other fluid being assayed.
Inventor(s):	Lindall; Arnold W. (Marine-on-St. Croix, MN), Elting; James J. (North Oaks, MN)
Assignee:	Immuno Nuclear Corporation (Stillwater, MN)
Application Number:	06/477,253
Patent Claims:	1. A method of bioassay of mammalian parathyroid peptides in biological or other fluids comprising: extracting from a measured volume of the biological or other fluid, with a support-antibody matrix specific to the N-terminal region of mammalian parathyroid hormone, mammalian parathyroid peptides to which the matrix is specific; contacting the extracted mammalian parathyroid peptides with cultured animal tissue, cultured animal cells, or tissue extract containing adenylate cyclase-coupled parathyroid hormone receptors in a measured volume of medium and under conditions suitable for the extracted mammalian parathyroid peptides to bind the parathyroid hormone receptors; and measuring the response to binding of the parathyroid hormone receptors. 2. The method of claim 1 wherein the mammalian parathyroid peptides are members of the group consisting of rat parathyroid peptides, bovine parathyroid peptides, porcine parathyroid peptides, and human parathyroid peptides. 3. The method of claim 2 wherein said members are human parathyroid peptides. 4. The method of claim 3 wherein said biological or other fluid is human serum or plasma. 5. The method of claim 1 wherein the support-antibody matrix comprises the antibody coupled to agarose and cross linked dextran activated by carbonlydiimidazole or the antibody coupled to agarose activated with cyanogen bromide. 6. The method of claim 1 wherein the extraction from the fluid of the mammalian parathyroid peptides to which the matrix is specific further comprises (a) contacting the measured quantity of the fluid with the support-antibody matrix specific to the N-terminal region of mammalian parathyroid hormone; (b) allowing under suitable conditions reaction of the matrix antibodies with mammalian parathyroid peptides to which they are specific to proceed substantially to equilibrium; (c) separating the support-antibody matrix and mammalian parathyroid peptides coupled thereto from the remaining fluid and uncoupled mammalian parathyroid peptides contained therein; (d) contacting the separated support-antibody matrix and mammalian parathyroid peptides coupled thereto with a decoupling solution under suitable conditions for decoupling the mammalian parathyroid peptides coupled to the support-antibody matrix; (e) allowing under suitable conditions substantial decoupling of the mammalian parathyroid peptides coupled to the support-antibody matrix; and (f) separating the remaining solution and mammalian parathyroid peptides contained therein from the support-antibody matrix. 7. The method of claim 6 wherein the fluid and support-antibody matrix are contacted per step (a) by adding the fluid and support-antibody matrix into an affinity chromatography column; the matrix antibodies are allowed to react substantially to equilibrium with mammalian parathyroid peptides to which they are specific per step (b) by maintaining contact of the matrix with the peptides in the column under suitable conditions until the reaction substantially reaches equilibrium; the support-antibody matrix and mammalian parathyroid peptides coupled thereto are separated from the remaining fluid and uncoupled mammalian parathyroid peptides contained therein per step (c) by allowing the remaining fluid and uncoupled peptides to drain through the column; the support antibody matrix and mammalian parathyroid peptide coupled thereto are contacted with the decoupling solution per step (d) by adding the decoupling solution to the column containing said matrix and coupled peptides; the mammalian parathyroid peptides coupled to the support-antibody matrix are allowed to substantially decouple per step (e) by maintaining contact of the decoupling solution and the matrix in the column until such substantial decoupling; and the remaining solution and mammalian parathyroid peptides contained therein are separated from the support-antibody matrix per step (f) by allowing the remaining solution and peptides contained therein to drain through the column. 8. The method of claim 6 wherein the mammalian parathyroid peptides contained in the remaining solution per step (f) are separated from the remaining solution. 9. The method of claim 8 wherein the mammalian parathyroid peptides contained in the remaining solution per step (f) are separated from the remaining solution by lyophilizing the remaining solution containing the mammalian parathyroid peptides. 10. The method of claim 9 wherein the product of lyophilization is reconstituted by the medium or a constituent of the medium. 11. The method of claim 1 wherein the volume of the medium is substantially less than the volume of the biological or other fluid. 12. The method of claim 1 wherein the cultured animal cells are an osteogenic sarcoma cell culture. 13. The method of claim 12 wherein the binding of the parathyroid hormone receptors is measured by assaying stimulated cAMP generation by the osteogenic sarcoma cell culture. 14. The method of claim 1 wherein the tissue extract is canine renal cortical plasma membranes. 15. As an article of manufacture, an extraction-bioassay kit comprising at least one vial containing a support-antibody matrix specific to the N-terminal region of mammalian parathyroid hormone and at least one vial containing an animal tissue preparation, animal cell preparation, or tissue extract preparation which may be reconstituted, reactivated, or used respectively as cultured animal tissue, cultured animal cells, or tissue extract containing adenylate cyclase-coupled parathyroid hormone receptors. 16. The extraction-bioassay kit of claim 15 wherein the support of the support-antibody matrix comprises agarose and cross linked dextran activated by carbonyldiimidazole or agarose activated with cyanogen bromide. 17. The extraction-bioassay kit of claim 15 wherein the N-terminal region of mammalian parathyroid hormone is a member of the group consisting of the N-terminal region of rat parathyroid hormone, N-terminal region of bovine parathyroid hormone, N-terminal region of bovine parathyroid hormone, N-terminal region of porcine parathyroid hormone, and N-terminal region of human parathyroid hormone. 18. The extraction-bioassay kit of claim 17 wherein said member is the N-terminal region of human parathyroid hormone.

Details for Patent 4,508,828

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-03-29